ALAMEDA, Calif.--(BUSINESS WIRE)--Celera Corporation (NASDAQ:CRA) and its collaborators at The University of Washington, WA, and Indiana University, IN, today announced the presentation of data from a research study that investigated the expression of KIF6 in a mouse Celera Corporation model. A key finding was that KIF6 was specifically expressed in macrophages and chondrocytes in mouse atherosclerotic lesions, but not in normal arteries. These data suggest a potential role for KIF6 in inflammatory processes of atherosclerotic lesions, processes that can result in the development of vulnerable plaques that may rupture, leading to coronary events. The research study results were presented on Saturday, April 10, at the 2010 Arteriosclerosis, Thrombosis and Vascular Biology Annual Conference under the auspices of the American Heart Association in San Francisco, CA.
